TY - JOUR
T1 - Detectability of Medication Errors With a STOPP/START-Based Medication Review in Older People Prior to a Potentially Preventable Drug-Related Hospital Admission
AU - Sallevelt, Bastiaan T.G.M.
AU - Egberts, Toine C.G.
AU - Huibers, Corlina J.A.
AU - Ietswaart, Jimmy
AU - Drenth-van Maanen, A. Clara
AU - Jennings, Emma
AU - O’Mahony, Cian
AU - Jungo, Katharina Tabea
AU - Feller, Martin
AU - Rodondi, Nicolas
AU - Sibille, François Xavier
AU - Spinewine, Anne
AU - van Puijenbroek, Eugène P.
AU - Wilting, Ingeborg
AU - Knol, Wilma
N1 - Funding Information:
This work is part of the project “OPERAM: OPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly” supported by the European Union's Horizon 2020 research and innovation program under the grant agreement No 634238, and by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 15.0137. The OPERAM project was also partially funded by the Swiss National Science Foundation (SNSF 320030_188549). The work of Katharina Tabea Jungo was supported by the Swiss National Science Foundation (SNSF), grant No NFP74 407440_167465. The opinions expressed herein are those of the authors and do not necessarily reflect the official views of the European Commission and the Swiss government. The funder of the study had no role in the study design, data collection, analysis and interpretation or writing of the report.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Introduction Multimorbidity and polypharmacy are risk factors for drug-related hospital admissions (DRAs) in the ageing population. DRAs caused by medication errors (MEs) are considered potentially preventable. The STOPP/START criteria were developed to detect potential MEs in older people.Objective The aim of this study was to assess the detectability of MEs with a STOPP/START-based in-hospital medication review in older people with polypharmacy and multimorbidity prior to a potentially preventable DRA.Methods Hospitalised older patients (n = 963) with polypharmacy and multimorbidity from the intervention arm of the OPERAM trial received a STOPP/START-based in-hospital medication review by a pharmacotherapy team. Readmissions within 1 year after the in- hospital medication review were adjudicated for drug-relatedness. A retrospective assessment was performed to determine whether MEs identified at the first DRA were detectable during the in-hospital medication review.Results In total, 84 of 963 OPERAM intervention patients ( 8.7%) were readmitted with a potentially preventable DRA, of which 72 patients (n = 77 MEs) were eligible for analysis. About half (48%, n = 37/77) of the MEs were not present during the in-hospital medication review and therefore were not detectable at that time. The pharmacotherapy team recommended a change in medication regimen in 50% ( n = 20/40) of present MEs, which corresponds to 26% (n = 20/77) of the total identified MEs at readmission. However, these recommendations were not implemented.Conclusion MEs identified at readmission were not addressed by a prior single in-hospital medication review because either these MEs occurred after the medication review (similar to 50%), or no recommendation was given during the medication review (similar to 25%), or the recommendation was not implemented (similar to 25%). Future research should focus on optimisation of the timing and frequency of medication review and the implementation of proposed medication recommendations.
AB - Introduction Multimorbidity and polypharmacy are risk factors for drug-related hospital admissions (DRAs) in the ageing population. DRAs caused by medication errors (MEs) are considered potentially preventable. The STOPP/START criteria were developed to detect potential MEs in older people.Objective The aim of this study was to assess the detectability of MEs with a STOPP/START-based in-hospital medication review in older people with polypharmacy and multimorbidity prior to a potentially preventable DRA.Methods Hospitalised older patients (n = 963) with polypharmacy and multimorbidity from the intervention arm of the OPERAM trial received a STOPP/START-based in-hospital medication review by a pharmacotherapy team. Readmissions within 1 year after the in- hospital medication review were adjudicated for drug-relatedness. A retrospective assessment was performed to determine whether MEs identified at the first DRA were detectable during the in-hospital medication review.Results In total, 84 of 963 OPERAM intervention patients ( 8.7%) were readmitted with a potentially preventable DRA, of which 72 patients (n = 77 MEs) were eligible for analysis. About half (48%, n = 37/77) of the MEs were not present during the in-hospital medication review and therefore were not detectable at that time. The pharmacotherapy team recommended a change in medication regimen in 50% ( n = 20/40) of present MEs, which corresponds to 26% (n = 20/77) of the total identified MEs at readmission. However, these recommendations were not implemented.Conclusion MEs identified at readmission were not addressed by a prior single in-hospital medication review because either these MEs occurred after the medication review (similar to 50%), or no recommendation was given during the medication review (similar to 25%), or the recommendation was not implemented (similar to 25%). Future research should focus on optimisation of the timing and frequency of medication review and the implementation of proposed medication recommendations.
KW - Association
KW - Criteria
KW - Events
KW - Metaanalysis
KW - Polypharmacy
UR - http://www.scopus.com/inward/record.url?scp=85141186162&partnerID=8YFLogxK
U2 - 10.1007/s40264-022-01237-5
DO - 10.1007/s40264-022-01237-5
M3 - Review article
C2 - 36319944
AN - SCOPUS:85141186162
SN - 0114-5916
VL - 45
SP - 1501
EP - 1516
JO - Drug Safety
JF - Drug Safety
IS - 12
ER -